EP3612274A4 - Administration parentérale non systémique d'agents tampons pour inhiber la métastase de tumeurs solides, l'hyperpigmentation et la goutte - Google Patents

Administration parentérale non systémique d'agents tampons pour inhiber la métastase de tumeurs solides, l'hyperpigmentation et la goutte Download PDF

Info

Publication number
EP3612274A4
EP3612274A4 EP18787621.4A EP18787621A EP3612274A4 EP 3612274 A4 EP3612274 A4 EP 3612274A4 EP 18787621 A EP18787621 A EP 18787621A EP 3612274 A4 EP3612274 A4 EP 3612274A4
Authority
EP
European Patent Office
Prior art keywords
hyperpigmentation
gout
parenteral administration
solid tumor
buffering agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18787621.4A
Other languages
German (de)
English (en)
Other versions
EP3612274A1 (fr
Inventor
Bruce J. Sand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampersand Biopharmaceuticals LLC
Original Assignee
Ampersand Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampersand Biopharmaceuticals LLC filed Critical Ampersand Biopharmaceuticals LLC
Publication of EP3612274A1 publication Critical patent/EP3612274A1/fr
Publication of EP3612274A4 publication Critical patent/EP3612274A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18787621.4A 2017-04-17 2018-04-17 Administration parentérale non systémique d'agents tampons pour inhiber la métastase de tumeurs solides, l'hyperpigmentation et la goutte Withdrawn EP3612274A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762602227P 2017-04-17 2017-04-17
US201762602358P 2017-04-20 2017-04-20
US201762602359P 2017-04-20 2017-04-20
US201762559360P 2017-09-15 2017-09-15
US201762559947P 2017-09-18 2017-09-18
US201762562725P 2017-09-25 2017-09-25
US201762609982P 2017-12-22 2017-12-22
US201862639904P 2018-03-07 2018-03-07
PCT/US2018/028017 WO2018195111A1 (fr) 2017-04-17 2018-04-17 Administration parentérale non systémique d'agents tampons pour inhiber la métastase de tumeurs solides, l'hyperpigmentation et la goutte

Publications (2)

Publication Number Publication Date
EP3612274A1 EP3612274A1 (fr) 2020-02-26
EP3612274A4 true EP3612274A4 (fr) 2021-05-26

Family

ID=63856054

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18787621.4A Withdrawn EP3612274A4 (fr) 2017-04-17 2018-04-17 Administration parentérale non systémique d'agents tampons pour inhiber la métastase de tumeurs solides, l'hyperpigmentation et la goutte

Country Status (7)

Country Link
EP (1) EP3612274A4 (fr)
JP (1) JP2020516690A (fr)
KR (1) KR20200042440A (fr)
CN (1) CN111093774A (fr)
AU (3) AU2018255294B2 (fr)
MX (1) MX390709B (fr)
WO (1) WO2018195111A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105499A1 (fr) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Méthodes et formulations pour l'administration transdermique
EP3681479B1 (fr) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Bicarbonate de sodium pour utilisation dans le traitement de la goutte et de troubles associés
US20190201327A1 (en) * 2017-09-25 2019-07-04 Ampersand Biopharmaceuticals, Inc. Topical applications of withaferin a
EP3870225A1 (fr) * 2018-10-23 2021-09-01 Ampersand Biopharmaceuticals, Inc. Méthodes et formulations pour l'administration transdermique d'agents de remodelage dermique
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
US20210059955A1 (en) * 2019-08-26 2021-03-04 RL Patents, LLC Systems and methods for decrystallization of uric acid
CN113181149A (zh) * 2021-06-11 2021-07-30 北京畅盛医药科技有限公司 一种治疗痛风性关节炎的皮肤外用药物制剂
US20230330041A1 (en) * 2020-08-27 2023-10-19 Beijing Changsheng Pharmaceutical Technology Co., Ltd. Application of tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt to drugs for treating hyperuricemia
CN116539880B (zh) * 2022-12-05 2023-12-08 四川大学华西医院 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途
CN116284814B (zh) * 2023-01-17 2025-02-14 杭州三式化妆品有限公司 超分子传明酸甘醇酸离子盐及其制备方法和应用
CN119925334A (zh) * 2023-11-06 2025-05-06 南京毓浠医药技术有限公司 一种含有氨甲环酸与维a酸的复方组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
WO2004008887A1 (fr) * 2002-07-23 2004-01-29 Phoenix Eagle Company Pty Ltd Composition produite a partir de fruits et/ou de legumes
CN106236937A (zh) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 能缓解痛风性关节炎的泡浴液

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176918A (en) * 1990-12-20 1993-01-05 Jones Jeffry L Topical medicament
JP2000508302A (ja) * 1996-04-04 2000-07-04 エフ．ホフマン―ラ ロッシュ エイジー 抗転移剤としてのテトラヒドロ―β―カルボリン誘導体の使用
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1998742A2 (fr) * 2006-03-08 2008-12-10 Nuviance, INC. Composition de médicament à libération transdermique et compositions topiques pour application cutanée
WO2010030395A2 (fr) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Analogues de la withaférine a et leurs utilisations
CN101897784A (zh) * 2009-05-27 2010-12-01 北京因科瑞斯医药科技有限公司 一种用于痛风的中药组合物及其制备方法
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011066379A2 (fr) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédé de diminution du phe intratumoral et d'une invasion induite par un acide
JP2014500867A (ja) * 2010-11-09 2014-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚浸透性および細胞侵入性（ｓｐａｃｅ）ペプチドとその使用法
US20140017157A1 (en) * 2011-03-29 2014-01-16 Neochemir Inc. Antitumor agent comprising carbon dioxide as an active ingredient
USRE47750E1 (en) * 2012-03-28 2019-12-03 University Of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine macrocylic conjugates
WO2016105499A1 (fr) * 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Méthodes et formulations pour l'administration transdermique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
WO2004008887A1 (fr) * 2002-07-23 2004-01-29 Phoenix Eagle Company Pty Ltd Composition produite a partir de fruits et/ou de legumes
CN106236937A (zh) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 能缓解痛风性关节炎的泡浴液

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Baking Soda Treatment for Gout", 5 November 2016 (2016-11-05), pages 1 - 3, XP055765385, Retrieved from the Internet <URL:https://web.archive.org/web/20161110122944/https://www.earthclinic.com/baking-soda-for-gout.html> [retrieved on 20210115] *
R. VERDOLINI ET AL: "Old fashioned sodium bicarbonate baths for the treatment of psoriasis in the era of futuristic biologics: An old ally to be rescued", JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 16, no. 1, 12 February 2005 (2005-02-12), UK, pages 26 - 29, XP055765406, ISSN: 0954-6634, DOI: 10.1080/09546630410024862 *

Also Published As

Publication number Publication date
AU2022241559B2 (en) 2023-07-27
MX390709B (es) 2025-03-21
CN111093774A (zh) 2020-05-01
MX2019012385A (es) 2022-03-15
AU2022241559A1 (en) 2022-10-27
AU2018255294A1 (en) 2019-12-05
AU2018255294B2 (en) 2022-07-28
WO2018195111A1 (fr) 2018-10-25
KR20200042440A (ko) 2020-04-23
EP3612274A1 (fr) 2020-02-26
AU2023254920A1 (en) 2023-11-16
JP2020516690A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
EP3612274A4 (fr) Administration parentérale non systémique d&#39;agents tampons pour inhiber la métastase de tumeurs solides, l&#39;hyperpigmentation et la goutte
EP3381161A4 (fr) Détection et récupération de dichotomie d&#39;agrégation de liaisons
EP3710008A4 (fr) Inhibition de runx1 pour le traitement de la vitréorétinopathie proliférative et d&#39;états associés à une transition épithéliale à mésenchymateuse
MA42950A (fr) Administration d&#39;agents de potentialisation de cftr modifiés au deutérium
EP3645146A4 (fr) Synthèse d&#39;oligosaccharides
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d&#39;utilisation
MA49847A (fr) Production enzymatique d&#39;hexoses
EP3329464A4 (fr) Transfert d&#39;attribut robuste pour une animation de personnage
EP3040355A4 (fr) Modificateur d&#39;asphalte et composition d&#39;asphalte le contenant
EP3318542A4 (fr) Composition d&#39;engrais pour une application sur les feuilles et comprenant du glutathion oxydé et un constituant d&#39;engrais
EP3457456A4 (fr) Composition pour couche fonctionnelle d&#39;accumulateur non aqueux, couche fonctionnelle pour accumulateur non aqueux et accumulateur non aqueux
EP3645040A4 (fr) Utilisation d&#39;anticorps anti-fam19a5 pour le traitement de cancers
FR2992855B1 (fr) Dispositif pour le massage et l&#39;application d&#39;une composition cosmetique
EP3247718A4 (fr) Modulation de variants de charge dans une composition d&#39;anticorps monoclonaux
FR2992856B1 (fr) Dispositif pour le massage et l&#39;application d&#39;une composition cosmetique
EP3327036A4 (fr) Anticorps anti-egfr spécifique d&#39;une tumeur et application associée
MA51873A (fr) Molécules probiotiques pour réduire la virulence d&#39;agents pathogènes
EP3437145A4 (fr) Approches pour l&#39;ingénierie de contraintes de jonctions tunnel magnétiques perpendiculaires (pmtj), et structures résultantes
MA47494A (fr) Nouvelles utilisations d&#39;anticorps anti-sirpg
FR3022462B1 (fr) Composition orale d&#39;anticorps anti-tnfalpha
EP3386350A4 (fr) Construction d&#39;oreiller garni de duvet
EP2956771A4 (fr) Procédés et compositions pour détection amplifiée d&#39;une électrochimiluminescence
EP3007773A4 (fr) Anticorps ige pour l&#39;inhibition d&#39;une métastase de tumeur
EP3397262A4 (fr) Combinaison d&#39;inhibiteur de hdac et d&#39;anticorps anti-pd-l1 pour le traitement de cancer des ovaires
EP3365743A4 (fr) Détection et régulation d&#39;affaissement pour tuiles de processeur

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/06 20060101ALI20210121BHEP

Ipc: A61K 9/06 20060101AFI20210121BHEP

Ipc: A61K 45/06 20060101ALI20210121BHEP

Ipc: A61K 33/42 20060101ALI20210121BHEP

Ipc: A61K 47/02 20060101ALI20210121BHEP

Ipc: A61K 33/10 20060101ALI20210121BHEP

Ipc: A61K 9/00 20060101ALI20210121BHEP

Ipc: A61P 17/00 20060101ALI20210121BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035040000

Ipc: A61K0009060000

A4 Supplementary search report drawn up and despatched

Effective date: 20210429

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/06 20060101AFI20210422BHEP

Ipc: A61K 9/00 20060101ALI20210422BHEP

Ipc: A61P 19/06 20060101ALI20210422BHEP

Ipc: A61K 33/42 20060101ALI20210422BHEP

Ipc: A61K 47/02 20060101ALI20210422BHEP

Ipc: A61K 33/10 20060101ALI20210422BHEP

Ipc: A61K 45/06 20060101ALI20210422BHEP

Ipc: A61P 17/00 20060101ALI20210422BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230524

18W Application withdrawn

Effective date: 20230601